{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/6afd71e149ecb9dfcb8a0f1a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What does the future hold for next-generation menin inhibition in AML?","description":"<p>The AML Hub was pleased to speak with Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What does the future hold for next-generation menin inhibition in AML?</p><p><br></p><p>During this interview, Wang discusses emerging strategies to optimize the efficacy of menin inhibitors for the treatment of acute myeloid leukemia (AML), including sequential treatment approaches to address acquired resistance, their integration into combination regimens for <em>KMT2A</em>-rearranged (<em>KMT2A</em>r) or <em>NPM1</em>-mutated (<em>NPM1</em>m) AML, and their use alongside other targeted therapies for patients with co-occurring mutations.</p><p><br></p><p>This educational resource is independently supported by Johnson &amp; Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p>","author_name":"Scientific Education Support"}